Inhibition of VEGF or VEGFR has been demonstrated an efficacy strategy in treating several tumors, including colon, stomach, breast, ovary, thyroid, kidney, liver, and non-small-cell lung cancers. This evidence concerns the gene KDR and non-small cell lung carcinoma.